Literature DB >> 30603361

Sarcopenia in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors.

Yuko Murata1, Yoshiki Kadoya1, Shoichi Yamada1, Tokio Sanke2.   

Abstract

AIMS: Sarcopenia, which shortens healthy life expectancy, has recently been attracting attention because the Japanese population is rapidly aging. In this preliminary study, we estimated the prevalence of elderly diabetic patients who were complicated with sarcopenia and searched for any related clinical factors.
METHODS: Elderly (≥65 years of age) Japanese patients with type 2 diabetes mellitus were recruited by asking doctors to supply candidates for the study. The prevalence of sarcopenia was estimated based on the criteria proposed by the Asian Working Group for Sarcopenia in 2014.
RESULTS: Two hundred eighty-eight patients (151 males) were accepted for the study. The prevalence of sarcopenia was 15.2% in males and 15.3% in females. Multiple logistic regression analysis indicated that sarcopenia was significantly correlated with serum high-sensitivity C-reactive protein in females, in addition to age and body mass index. Female patients were then classified into four groups according to the presence or absence of impaired muscle mass and/or impaired strength. Serum high-sensitivity C-reactive protein was significantly higher in the sarcopenia group (those with impaired muscle mass and impaired strength) than in the other three groups.
CONCLUSIONS: After clarifying the prevalence of sarcopenia in elderly Japanese patients with type 2 diabetes mellitus, we found that serum high-sensitivity C-reactive protein was significantly higher in female patients with sarcopenia than in female patients without sarcopenia. Elevated serum high-sensitivity C-reactive protein requires impaired muscle mass and impaired strength.

Entities:  

Keywords:  Elderly patients; High-sensitivity C-reactive protein; Sarcopenia; Type 2 diabetes mellitus

Year:  2017        PMID: 30603361      PMCID: PMC6224944          DOI: 10.1007/s13340-017-0339-6

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  29 in total

1.  Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study.

Authors:  Seok Won Park; Bret H Goodpaster; Elsa S Strotmeyer; Nathalie de Rekeneire; Tamara B Harris; Ann V Schwartz; Frances A Tylavsky; Anne B Newman
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

2.  Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.

Authors:  Xiaonan Wang; Zhaoyong Hu; Junping Hu; Jie Du; William E Mitch
Journal:  Endocrinology       Date:  2006-06-15       Impact factor: 4.736

3.  Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways.

Authors:  Ekaterina L Kovacheva; Amiya P Sinha Hikim; Ruoqing Shen; Indranil Sinha; Indrani Sinha-Hikim
Journal:  Endocrinology       Date:  2009-12-18       Impact factor: 4.736

4.  Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes.

Authors:  Maria Pedersen; Helle Bruunsgaard; Nina Weis; Helle W Hendel; Bente U Andreassen; Ebbe Eldrup; Flemming Dela; Bente K Pedersen
Journal:  Mech Ageing Dev       Date:  2003-04       Impact factor: 5.432

5.  Sarcopenic obesity and inflammation in the InCHIANTI study.

Authors:  Matthew A Schrager; E Jeffrey Metter; Eleanor Simonsick; Alessandro Ble; Stefania Bandinelli; Fulvio Lauretani; Luigi Ferrucci
Journal:  J Appl Physiol (1985)       Date:  2006-11-09

6.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

7.  Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS).

Authors:  Tae Nyun Kim; Man Sik Park; Sae Jeong Yang; Hye Jin Yoo; Hyun Joo Kang; Wook Song; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 19.112

8.  Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study.

Authors:  Ronenn Roubenoff; Helen Parise; Hélène A Payette; Leslie W Abad; Ralph D'Agostino; Paul F Jacques; Peter W F Wilson; Charles A Dinarello; Tamara B Harris
Journal:  Am J Med       Date:  2003-10-15       Impact factor: 4.965

Review 9.  Testosterone supplementation for aging-associated sarcopenia.

Authors:  Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2003-11       Impact factor: 6.053

10.  White matter lesions as a feature of cognitive impairment, low vitality and other symptoms of geriatric syndrome in the elderly.

Authors:  Kazuki Sonohara; Koichi Kozaki; Masahiro Akishita; Kumiko Nagai; Hiroshi Hasegawa; Masafumi Kuzuya; Koutaro Yokote; Kenji Toba
Journal:  Geriatr Gerontol Int       Date:  2008-06       Impact factor: 2.730

View more
  8 in total

Review 1.  Sarcopenia in people living with the Human Immunodeficiency Virus: a systematic review and meta-analysis.

Authors:  Vitor H F Oliveira; Ana L Borsari; Allison R Webel; Kristine M Erlandson; Rafael Deminice
Journal:  Eur J Clin Nutr       Date:  2020-04-27       Impact factor: 4.016

Review 2.  A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors.

Authors:  Anna Izzo; Elena Massimino; Gabriele Riccardi; Giuseppe Della Pepa
Journal:  Nutrients       Date:  2021-01-09       Impact factor: 5.717

3.  Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.

Authors:  Daisuke Yabe; Kosuke Shiki; Keiko Suzaki; Thomas Meinicke; Yutaro Kotobuki; Kenichiro Nishida; Douglas Clark; Atsutaka Yasui; Yutaka Seino
Journal:  BMJ Open       Date:  2021-04-07       Impact factor: 2.692

4.  Should knee extension strength testing be implemented as a screening test for identifying probable and confirmed sarcopenia in older T2DM patients?

Authors:  Ofer Kis; Assaf Buch; Roy Eldor; Amir Rubin; Ayelet Dunsky; Naftali Stern; Daniel S Moran
Journal:  Eur Rev Aging Phys Act       Date:  2022-01-27       Impact factor: 3.878

5.  Sex-Specific Associations Between Low Muscle Mass and Glucose Fluctuations in Patients With Type 2 Diabetes Mellitus.

Authors:  Xiulin Shi; Wenjuan Liu; Lulu Zhang; Fangsen Xiao; Peiying Huang; Bing Yan; Yiping Zhang; Weijuan Su; Qiuhui Jiang; Mingzhu Lin; Wei Liu; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-13       Impact factor: 6.055

Review 6.  The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review.

Authors:  Chen-Ning Wu; Kai-Jen Tien
Journal:  J Diabetes Res       Date:  2020-07-09       Impact factor: 4.011

7.  Bofutsushosan improves gut barrier function with a bloom of Akkermansia muciniphila and improves glucose metabolism in mice with diet-induced obesity.

Authors:  Shiho Fujisaka; Isao Usui; Allah Nawaz; Yoshiko Igarashi; Keisuke Okabe; Yukihiro Furusawa; Shiro Watanabe; Seiji Yamamoto; Masakiyo Sasahara; Yoshiyuki Watanabe; Yoshinori Nagai; Kunimasa Yagi; Takashi Nakagawa; Kazuyuki Tobe
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

8.  Association between sarcopenia and the severity of diabetic polyneuropathy assessed by nerve conduction studies in Japanese patients with type 2 diabetes mellitus.

Authors:  Kentaro Mikura; Eriko Kodama; Tatsuya Iida; Hideyuki Imai; Mai Hashizume; Yasuyoshi Kigawa; Rie Tadokoro; Chiho Sugisawa; Kei Endo; Toru Iizaka; Fumiko Otsuka; Shoichiro Nagasaka
Journal:  J Diabetes Investig       Date:  2022-03-21       Impact factor: 3.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.